RECRUITING

Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This clinical trial investigates the role of contrast enhanced ultrasound (CEUS) in identifying cystic breast masses as benign or malignant. Ultrasound is a diagnostic imaging test that uses sound waves to make pictures of the body without using radiation (x-rays). Ultrasounds are widely used to diagnose many diseases in the body. This trial may help researchers learn if using CEUS will help in determining whether or not an ultrasound guided biopsy is necessary.

Official Title

Characterizing Breast Masses Using an Integrative Framework of Machine Learning and Radiomics

Quick Facts

Study Start:2020-11-05
Study Completion:2025-11-05
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06171607

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Newly diagnosed breast masses assigned as BIRADS 4a, 4b, 4c or 5 by conventional US and recommended for ultrasound guided biopsy
  2. * Age \>= 18 years
  3. * Female
  1. * Contraindications to microbubble contrast: Patients who have a known pulmonary hypertension and any known hypersensitivity to US contrast agent
  2. * Women who are pregnant, possibly pregnant, or lactating
  3. * Women currently undergoing neoadjuvant chemotherapy
  4. * Women \< 18 years of age
  5. * Masses in the same breast that had prior lumpectomy for cancer
  6. * Women with cancer in the same breast will be excluded however, women with cancer in the contralateral breast will be eligible to participate in the study
  7. * Women with an allergy to perflutren
  8. * Prior history of biopsy for that specific lesion

Contacts and Locations

Study Contact

Janet Jaime
CONTACT
323-865-3205
Janet.jaime@med.usc.edu

Principal Investigator

Bino A Varghese, PhD
PRINCIPAL_INVESTIGATOR
University of Southern California

Study Locations (Sites)

Los Angeles County-USC Medical Center
Los Angeles, California, 90033
United States
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033
United States

Collaborators and Investigators

Sponsor: University of Southern California

  • Bino A Varghese, PhD, PRINCIPAL_INVESTIGATOR, University of Southern California

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-11-05
Study Completion Date2025-11-05

Study Record Updates

Study Start Date2020-11-05
Study Completion Date2025-11-05

Terms related to this study

Additional Relevant MeSH Terms

  • Breast Carcinoma